News from invitae corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

May 27, 2022, 07:00 ET Invitae to Present at Upcoming Investor Conferences

Invitae (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will participate in the following...

May 26, 2022, 17:05 ET New Research Demonstrates Genetic Information Can Transform Cancer Care, Guidelines Remain a Barrier to Patient Access

Invitae (NYSE: NVTA), a leading medical genetics company, today announced eight studies to be presented at the 2022 American Society of Clinical...

May 19, 2022, 06:30 ET Invitae Launches Expanded Pharmacogenomics Panel and Specialized Mental Health Panel

Invitae (NYSE: NVTA), a leading medical genetics company, today announced the commercial availability of the expanded Invitae Pharmacogenomics (PGx)...

May 03, 2022, 16:05 ET Invitae Reports $123.7 Million in Revenue in First Quarter of 2022 and Extends Cash Runway

— Executing toward 2022 plan, generating near 20% revenue growth, with $885 million in ending cash*, an annualized burn reduction of greater than...

Apr 20, 2022, 06:59 ET Invitae to Announce First Quarter 2022 Financial Results on Tuesday, May 3, 2022

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its first quarter 2022 financial results on ...

Apr 04, 2022, 06:30 ET Invitae Introduces First Comprehensive Genetic Test Suite for Neurodevelopmental Disorders

Invitae (NYSE: NVTA), a leading medical genetics company, today announced the full commercial launch of its Neurodevelopmental Disorders (NDD)...

Mar 29, 2022, 06:30 ET Introducing Invitae Digital Health--A Personalized Health Management Platform That Leverages Genomic Insights to Inform Health Decisions for Patients and Clinicians

Invitae (NYSE: NVTA), a leading medical genetics company, today announced the launch of Invitae Digital Health—a connected digital health platform...

Mar 17, 2022, 06:30 ET Invitae Launches Full Access to its Liquid-Based Personalized Cancer Monitoring Platform to Help Detect Disease Earlier

Invitae (NYSE: NVTA), a leading medical genetics company, today announced full access to its Personalized Cancer Monitoring (PCMTM) platform to help...

Mar 15, 2022, 16:30 ET Invitae Publishes the 2022 Environmental, Social and Governance Report

Invitae (NYSE: NVTA), a leading medical genetics company, today released its 2022 Environmental, Social and Governance (ESG) Report summarizing the...

Feb 24, 2022, 16:05 ET Invitae Reports $460.4 Million in Annual Revenue Driven by 1.17 Million in Billable Volume in 2021

Invitae (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the fourth quarter and year ended...

Feb 16, 2022, 12:02 ET Invitae запускает продажи своих тест-наборов для диагностики рака CE-IVD в Европе

Feb 16, 2022, 11:16 ET Invitae lance ses premiers kits de dépistage du cancer CE-IVD en Europe

Feb 16, 2022, 10:28 ET Invitae bringt seine ersten CE-IVD-Krebstestkits in Europa auf den Markt

Feb 16, 2022, 10:24 ET Invitae wprowadza w Europie swoje pierwsze testy CE-IVD do diagnozowania nowotworów

Feb 16, 2022, 08:36 ET Společnost Invitae uvádí na evropský trh své první soupravy CE-IVD pro testování rakoviny

Feb 16, 2022, 08:13 ET Spoločnosť Invitae uvádza na trh svoje prvé CE-IVD súpravy na testovanie rakoviny v Európe

Feb 16, 2022, 07:19 ET Invitae lanza sus primeros kits de pruebas de cáncer CE-IVD en Europa

Feb 16, 2022, 03:00 ET Invitae Launches its First CE-IVD Cancer Testing Kits In Europe

Invitae (NYSE: NVTA), a leading medical genetics company, today announced the availability of FusionPlex Dx® and LiquidPlex Dx™ in Europe, part of...

Feb 10, 2022, 06:59 ET Invitae to Announce Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its fourth quarter and full year 2021...

Feb 03, 2022, 16:01 ET Invitae to Present at Upcoming Investor Conferences

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will participate in virtual ...

Feb 03, 2022, 14:37 ET Invitae Supports the Biden Administration's Advancement of the Cancer Moonshot, Enhanced Recommendations on Genetic Testing for Cancer Treatment

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, applauds the Biden Administration's announcement to reignite the Cancer...

Jan 10, 2022, 06:59 ET Invitae Reports Preliminary 2021 Revenue of More Than $458 Million and Billable Volume of More Than 1.16 Million

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, announced preliminary unaudited full-year 2021 revenue, billable volume and...

Jan 05, 2022, 07:30 ET Invitae to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, chief executive officer, will present...

Nov 08, 2021, 16:05 ET Invitae Reports $114.4 Million in Revenue Driven by 296,000 in Billable Volume in Third Quarter of 2021

Invitae (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the third quarter ended September 30,...

Nov 08, 2021, 08:00 ET Northwestern University and Invitae Present New Research Highlighting the Importance of Genetic Testing for Cardiovascular Conditions at the American Heart Association Scientific Sessions

Investigators from Northwestern University Feinberg School of Medicine and Invitae (NYSE: NVTA), a medical genetics company, will present the results ...